MedTrace Logo

Body Weight Response With Disulfiram in Humans

NCT05162001 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-12-17

No results posted yet for this study

Summary

Overweight and obesity due to food that exceeds the requirements is an increasingly common global problem. Lifestyle intervention and anorectic drugs result in minimal weight loss, which tends to be easily regained. In addition, drugs tend to have too many side effects and have had to be withdrawn from management schemes and even from the market. Disulfiram (Antabuse®️) is approved by the Food and Drug Administration against chronic alcohol addiction. In a mouse study, disulfiram prevented body weight gain and negated the adverse impact of an obesogenic diet on insulin; used properly it is a safe drug. Carrying out a testing-concept study with disulfiram will allow the establishment of guidelines on clinical studies focused on its use as an adjunct in the reduction and control of body weight.

Conditions

  • Obesity; Drug

Interventions

DRUG

Disulfiram 250 mg

Disulfiram used qd during nine weeks to observe effects on body weight

Sponsors & Collaborators

  • Laboratorios Doctor Macías

    collaborator UNKNOWN

  • Universidad de Guanajuato

    lead OTHER

Principal Investigators

  • Alejandro E Macias, MD · Universidad de Guanajuato

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-21
Primary Completion
2022-01-31
Completion
2022-04-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05162001 on ClinicalTrials.gov